NovoRapid FlexPen (Insulin Aspart 100 U/mL) by Novo Nordisk is a pharmaceutical-grade rapid-acting insulin analogue delivered via a prefilled FlexPen injectable pen. Insulin aspart is a recombinant human insulin analogue with a single amino acid substitution that accelerates subcutaneous absorption relative to regular human insulin, making it one of the most extensively researched prandial insulin analogues in clinical and endocrinological literature.
 
✔ Key Research Insights
Studied for its rapid onset of action, with documented commencement of glucose-lowering activity within 10–20 minutes of subcutaneous administration in research subjects
Investigated for its superior postprandial glucose control relative to regular human insulin in comparative clinical trials involving Type 1 and Type 2 diabetic subject populations
Researched for its predictable absorption profile and consistent pharmacodynamic activity, associated with reduced inter-subject and intra-subject glycaemic variability in clinical observations
Examined for its dual mechanism of promoting cellular glucose uptake and suppressing hepatic glucose output in documented subject populations
Documented for its compatibility with long-acting basal insulin formulations in basal-bolus therapy protocols referenced across international diabetes management guidelines
Manufactured by Novo Nordisk to pharmaceutical-grade insulin quality and safety standards
 
📦 Product Specifications
Manufacturer: Novo Nordisk
Product: NovoRapid FlexPen
Molecule: Insulin Aspart
Concentration: 100 U/mL
Appearance: Clear, colorless injectable solution
Form: Prefilled FlexPen (subcutaneous injection)
Volume: Box of 5 prefilled pens
Clinical reference: dosage should be determined by a qualified healthcare professional. Subcutaneous administration immediately before meals is indicated per documented clinical protocols.
 
⚙ How It Works
Insulin aspart is a rapid-acting recombinant human insulin analogue in which proline at position B28 is substituted with aspartic acid. This single amino acid modification reduces the tendency of insulin molecules to self-associate into hexamers at the injection site in research subjects, facilitating faster dissociation into monomeric form and correspondingly more rapid subcutaneous absorption relative to regular human insulin. Following subcutaneous administration, insulin aspart binds to insulin receptors on muscle and adipose tissue cells, stimulating cellular glucose uptake and concurrently suppressing hepatic glucose production, thereby attenuating postprandial hyperglycaemic excursions. Its documented pharmacokinetic profile — onset within 10–20 minutes, peak activity at approximately 1–3 hours, and total duration of action of 3–5 hours — closely replicates the physiological postprandial insulin secretion pattern of the endogenous pancreas, as noted in comparative pharmacokinetic literature. In basal-bolus therapy protocols, insulin aspart is referenced as the prandial component, administered in conjunction with a long-acting basal insulin to address both fasting and postprandial glycaemic parameters across documented clinical populations.
 
⭐ Product Overview
Manufactured by Novo Nordisk, a globally recognized leader in insulin research, development, and pharmaceutical-grade production
Prefilled FlexPen delivery system supporting precise, consistent, and hygienic subcutaneous dosing per administration
Rapid-acting insulin analogue with a well-documented pharmacokinetic profile and established clinical superiority over regular human insulin in postprandial glucose management
Indicated for mealtime insulin coverage in both Type 1 and Type 2 diabetes management, as referenced across international endocrinological and diabetes care guidelines
Widely recognized in clinical and regulatory literature under the insulin aspart and NovoRapid designations worldwide